Pneumococcal Infections
📧 Sign up to get email alerts when something new happens for Pneumococcal Infections.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-09-23Clinical Trial Update: Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024) [Phase 3]
Phase 3 trial update evaluating safety and immunogenicity of catch-up vaccination regimens for V114; completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-08-23Clinical Trial Update: A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION) [Phase 3]
Phase 3 trial evaluating interchangeability of V114 and Prevnar 13 in healthy infants has completed; results were posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-08-10Clinical Trial Update: Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10
A completed clinical trial evaluating immune response to serotype 19A Pneumococcus in children vaccinated with PCV10.
-
CLINICAL_TRIALS trial_result · 2021-06-16Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE) [Phase 3]
Phase 3 trial evaluating safety, tolerability, and immunogenicity of V116 in children with sickle cell disease has completed; results posted…
-
CLINICAL_TRIALS trial_result · 2021-05-06Clinical Trial Update: Immunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People Versus Diabetic Patients [Phase 4]
Phase 4 clinical trial comparing immunogenicity after revaccination with the 23-valent pneumococcal polysaccharide vaccine between healthy e…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-04-12Clinical Trial Update: Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020) [Phase 3]
Phase 3 trial updating lot-to-lot consistency of V114 in healthy adults has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-03-18Clinical Trial Update: Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE) [Phase 3]
Phase 3 trial update reporting safety and immunogenicity data for V114 in healthy adults (Pneumococcal infections).
-
CLINICAL_TRIALS trial_result · 2021-03-02Clinical Trial Update: Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants [Phase 2]
Phase 2 trial update on safety and immunogenicity of a multivalent pneumococcal vaccine in healthy infants completed with posted results.
-
CLINICAL_TRIALS trial_result · 2021-01-15Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY) [Phase 3]
Phase 3 trial evaluating safety, tolerability, and immunogenicity of V114 followed by PNEUMOVAX23 in adults at increased risk for pneumococc…
-
CLINICAL_TRIALS trial_result · 2021-01-06Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH) [Phase 3]
Phase 3 trial assessing safety, tolerability, and immunogenicity of V114 followed by PNEUMOVAX23 in adults 50+ completed; results posted in …
-
CLINICAL_TRIALS trial_result · 2020-11-25Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018) [Phase 3]
A Phase 3 study evaluating the safety, tolerability, and immunogenicity of V114 followed by PNEUMOVAX23 in adults with HIV; trial completed …
-
CLINICAL_TRIALS trial_result · 2020-06-29Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU) [Phase 3]
Phase 3 study evaluating safety, tolerability, and immunogenicity of the pneumococcal conjugate vaccine V114 when administered with an influ…
-
CLINICAL_TRIALS trial_result · 2020-06-04Clinical Trial Update: A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age [Phase 2]
Phase 2 trial update for a multivalent pneumococcal conjugate vaccine in healthy adults 50-85; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2020-04-20Clinical Trial Update: Immunogenicity and Safety Study of NBP606 in Healthy Toddlers [Phase 3]
Phase 3 trial update reporting immunogenicity and safety of NBP606 in healthy toddlers for pneumococcal infections.
-
CLINICAL_TRIALS trial_result · 2020-04-20Clinical Trial Update: Immunogenicity and Safety Study of NBP606 in Healthy Infants [Phase 3]
Phase 3 immunogenicity and safety study of NBP606 in healthy infants completed.
-
CLINICAL_TRIALS trial_result · 2020-02-05Clinical Trial Update: Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029) [Phase 3]
Phase 3 trial evaluating safety and immunogenicity of sequential administration of Prevnar 13 and Pneumovax 23 in adults 50+; study complete…
-
CLINICAL_TRIALS trial_result · 2020-01-02Clinical Trial Update: Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine [Phase 3]
Phase 3 trial update assessing immunogenicity of GSK's 10-valent pneumococcal conjugate vaccine has completed.
-
CLINICAL_TRIALS trial_result · 2019-12-26Clinical Trial Update: Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age [Phase 2]
Phase 2 trial update evaluating safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in adults aged 60-64; results post…
-
CLINICAL_TRIALS trial_result · 2019-12-10Clinical Trial Update: A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years. [Phase 3]
A Phase 3 trial evaluated safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in Japanese adults and adolescents (6-64 y…
-
CLINICAL_TRIALS trial_result · 2019-10-23Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008) [Phase 2]
Phase 2 trial evaluating two lots of V114 in healthy infants to assess safety, tolerability, and immunogenicity has completed with results p…
-
CLINICAL_TRIALS trial_result · 2019-08-20Clinical Trial Update: Enhancing a Sustainable Pharmacy-based Immunization Program in Two States [NA]
Completed clinical trial assessing a sustainable pharmacy-based immunization program in two states; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-08-14Clinical Trial Update: Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007) [Phase 2]
Phase 2 trial evaluating safety, tolerability, and immunogenicity of V114 compared with Prevnar 13 in adults ≥65 previously vaccinated with …
-
CLINICAL_TRIALS trial_result · 2019-04-30Clinical Trial Update: Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004) [Phase 1, Phase 2]
A Phase 1/2 trial evaluating safety, tolerability, and immunogenicity of the V114 pneumococcal vaccine in healthy adults and infants complet…
-
CLINICAL_TRIALS trial_result · 2019-04-30Clinical Trial Update: A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003) [Phase 2]
Phase 2 trial comparing Pneumococcal Conjugate Vaccine V114 to a marketed vaccine (V114-003) for Pneumococcal Infections; completed with res…
-
CLINICAL_TRIALS trial_result · 2019-04-02Clinical Trial Update: Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006) [Phase 2]
Phase 2 trial evaluating safety, tolerability, and immunogenicity of two V114 formulations in adults 50+ with completed results.